Mitruka K.,National Center for HIV AIDS |
Tsertsvadze T.,and Clinical Immunology Research Center |
Butsashvili M.,Neolab |
Gamkrelidze A.,National Center for Disease Control and Public Health of Georgia |
And 15 more authors.
Morbidity and Mortality Weekly Report | Year: 2015
What is already known on the topic? Hepatitis C virus (HCV) infection is a serious health problem that affects an estimated 130–170 million persons globally and results in an estimated 700,000 deaths annually. In 2013, new all-oral, well-tolerated regimens were licensed that can cure >90% of HCV infections. The country of Georgia has one of the world’s highest estimated HCV prevalences. What is added by this report? In April 2015, Georgia launched a hepatitis C elimination program that will initially focus on treating HCV-infected persons who have severe liver disease with new curative regimens, providing discounted HCV diagnostics to all persons, and building capacity to eventually diagnose and treat all Georgians infected with HCV. A national serosurvey was launched in May 2015, and seven clinical sites have opened to diagnose and treat HCV. Georgia is scaling up capacity to meet the high demand for HCV treatment. What are the implications for public health practice? Georgia has increased access to HCV testing and treatment as part of preparatory phase of a national HCV control program with goals for the elimination of HCV transmission and disease in the country. Georgia’s program can provide information and experience that will assist similar efforts in other parts of the world. © 2015, Department of Health and Human Services. All rights reserved.
PubMed | Karolinska Institutet, Regional Health Service Lazio Region, Libra Foundation, University of Plymouth and 212 more.
Type: | Journal: Clinical and translational allergy | Year: 2017
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (